Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group

被引：0
|
作者：
Martin Fenner
Christoph Oing
Annette Dieing
Thomas Gauler
Karin Oechsle
Anja Lorch
Marcus Hentrich
Hans-Georg Kopp
Carsten Bokemeyer
Friedemann Honecker
机构：
[1] Hannover Medical School,Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
[2] University Medical Center Hamburg-Eppendorf,Department of Oncology, Hematology and Bone Marrow Transplantation and Section of Pneumology
[3] Vivantes Hospital am Urban,Department of Hematology and Oncology
[4] Heinrich Heine University Medical Center Essen,Department of Radiotherapy and Radiation Oncology
[5] University Medical Center Duesseldorf,Genitourinary Medical Oncology, Department of Urology
[6] Red Cross Hospital Munich,Department of Internal Medicine III, Hematology and Oncology
[7] University Medical Center Tuebingen,Department of Oncology, Hematology, Clinical Immunology, Rheumatology and Pulmonology
[8] Robert-Bosch-Centrum für Tumorerkrankungen,Department of Molecular Oncology and Pneumological Oncology
[9] Robert-Bosch Hospital,undefined
[10] ZeTuP Tumor and Breast Center,undefined
[11] DataCite,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词：
Germ cell cancer; Testicular cancer; mTOR; Everolimus; Refractory; Cisplatin resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：717 / 723
页数：6
相关论文
共 50 条
  • [21] Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
    Kroiss, Matthias
    Quinkler, Marcus
    Johanssen, Sarah
    van Erp, Nielka P.
    Lankheet, Nienke
    Poellinger, Alexander
    Laubner, Katharina
    Strasburger, Christian J.
    Hahner, Stefanie
    Mueller, Hans-Helge
    Allolio, Bruno
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10): : 3495 - 3503
  • [22] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
    Morschhauser, Franck
    Tilly, Herve
    Chaidos, Aristeidis
    McKay, Pamela
    Phillips, Tycel
    Assouline, Sarit
    Batievi, Connie Lee
    Campbell, Phillip
    Ribrag, Vincent
    Damaj, Gandhi Laurent
    Dickinson, Michael
    Jurczak, Wojciech
    Kazmierczak, Maciej
    Opat, Stephen
    Radford, John
    Schmitt, Anna
    Yang, Jay
    Whalen, Jennifer
    Agarwal, Shefali
    Adib, Deyaa
    Salles, Gilles
    LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
  • [23] Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors:: a study of the German Testicular Cancer Study Group
    Bokemeyer, C.
    Oechsle, K.
    Honecker, F.
    Mayer, F.
    Hartmann, J. T.
    Waller, C. F.
    Boehlke, I.
    Kollmannsberger, C.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 448 - 453
  • [24] Anlotinib plus oral fluoropyrimidine S1 in treating patients with refractory or relapsed small cell lung cancer (SALTER TRIAL): An open-label, multicenter, single-arm, phase II trial
    Wang, W.
    Lv, D.
    Wu, X.
    Ye, J.
    Zhou, C.
    Wang, J.
    Ling, L.
    Yang, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1164 - S1164
  • [25] Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study
    Cao, Xin-Xin
    Jin, Jie
    Fu, Cheng-Cheng
    Yi, Shu-Hua
    Zhao, Wei-Li
    Sun, Zi-Min
    Yang, Wei
    Li, Deng-Ju
    Cui, Guo-Hui
    Hu, Jian-da
    Liu, Ting
    Song, Yong-Ping
    Xu, Bing
    Zhu, Zun-Min
    Xu, Wei
    Zhang, Ming-Zhi
    Tian, Ya-Min
    Zhang, Bin
    Zhao, Ren-Bin
    Zhou, Dao-Bin
    ECLINICALMEDICINE, 2022, 52
  • [26] Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
    Necchi, A.
    Lo Vullo, S.
    Giannatempo, P.
    Raggi, D.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Pennati, M.
    Zaffaroni, N.
    Perrone, F.
    Busico, A.
    Colecchia, M.
    Nicolai, N.
    Mariani, L.
    Salvioni, R.
    ANNALS OF ONCOLOGY, 2017, 28 (06) : 1346 - 1351
  • [27] RESULTS OF A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF LENALIDOMIDE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
    O'Brien, Maureen
    Alonzo, Todd
    Cooper, Todd
    Levine, John
    Brown, Patrick
    Slone, Tamra
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Quan, Jackie
    Simcock, Mathew
    Weiss, Daniel
    Zimmerman, Linda
    Kolb, Edward
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [28] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL
    Xu, Xiaoting
    Huan, Jian
    Miao, Hui
    Wang, Hao
    Wang, Yue
    Zhu, Hongyu
    Jiang, Jun
    Zhou, Juying
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384
  • [29] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
    Lan, Chunyan
    Shen, Jingxian
    Wang, Yin
    Li, Jundong
    Liu, Zhimin
    He, Mian
    Cao, Xinping
    Ling, Jiayu
    Huang, Jiaming
    Zheng, Min
    Zou, Guorong
    Yan, Haowen
    Liu, Qing
    Yang, Fan
    Wei, Wei
    Deng, Yanhong
    Xiong, Ying
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
  • [30] Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
    Lan, Chunyan
    Huang, Xin
    Shen, Jing-Xian
    Wang, Yin
    Xiong, Ying
    Li, Jundong
    Cao, Xinping
    Deng, Yanhong
    He, Mian
    Zou, Guorong
    Wang, Xiaodi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345